115 results
Page 3 of 6
8-K
EX-99.1
aulfiho 8tzcr
11 Feb 21
Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
o6ix4qqtj aw6nyi
11 Jan 21
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Total Revenues and Provides Commercial Update
8:06am
8-K
EX-99.1
r0tusogm 7oh
2 Nov 20
Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress
4:11pm
8-K
fag2d2fw9vad
25 Sep 20
Departure of Directors or Certain Officers
9:22am
8-K
EX-10.2
gy09czrzq1uu8
25 Sep 20
Departure of Directors or Certain Officers
9:22am
8-K
EX-10.1
ckwq wssq3
25 Sep 20
Departure of Directors or Certain Officers
9:22am
8-K
EX-99.1
nx0 hwszngznkmk
4 Aug 20
Karyopharm Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress
7:13am
8-K
EX-99.1
shwn4nhw
14 Jul 20
Karyopharm Announces Preliminary Unaudited Second Quarter
7:08am
424B5
yye1xiskbsz6
5 May 20
Prospectus supplement for primary offering
5:05pm
8-K
EX-1.1
qgxwuk sa
4 Mar 20
Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock
4:22pm
424B5
kgnr9v7eidyl3856bh
4 Mar 20
Prospectus supplement for primary offering
4:15pm
424B5
xv77hgxs5ld9
2 Mar 20
Prospectus supplement for primary offering
4:21pm
8-K
EX-99.1
l5ktf19lqd4 omo1piw
13 Feb 20
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress
7:09am
8-K
EX-99.1
vx9a 12q6w09
13 Jan 20
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
7:12am